← Back to Search

Contingency Management for Psychosis

N/A
Recruiting
Led By Rachel Rabin, Ph. D.
Research Sponsored by Douglas Mental Health University Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 28
Awards & highlights

Study Summary

This trial will study the brain changes of people with psychosis who stop using cannabis for 28 days, compared to a control group who continue using.

Who is the study for?
This trial is for adults who use cannabis heavily and either have psychosis or no psychiatric conditions. Participants must speak English or French, have an IQ over 75, and be stable on medications if they have psychosis. They can't join if they use other psychoactive substances, are suicidal, pregnant, need hospitalization for medical issues, take psychotropic meds (except those with psychosis), or have MRI contraindications.Check my eligibility
What is being tested?
The study examines how stopping cannabis affects brain function in people with and without psychosis over 28 days. It involves random assignment to a group that quits using cannabis or a control group that continues as usual. Brain changes will be monitored using MRI scans before and after the abstinence period.See study design
What are the potential side effects?
There may not be direct side effects from the interventions since this trial focuses on observing changes during cannabis abstinence rather than testing a drug; however, participants might experience withdrawal symptoms like irritability, sleep problems, cravings for cannabis or mood swings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in behavior during fMRI task
Change in fMRI brain activity pattern
Secondary outcome measures
Change in brain morphology: cortical thickness
Change in brain morphology: diffusion
Change in brain morphology: gray matter volume

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: Psychosis patients with cannabis use (Abstinent)Experimental Treatment1 Intervention
Psychosis patients with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
Group II: Non-Psychiatric controls with cannabis use (Abstinent)Experimental Treatment1 Intervention
Non-Psychiatric controls with cannabis use will receive contingency management to encourage cannabis abstinence for 28 days
Group III: Psychosis patients with cannabis use (Non-abstinent)Active Control1 Intervention
Psychosis Patients with cannabis use who will continue to use cannabis as usual
Group IV: Non-Psychiatric controls with cannabis use (Non-abstinent)Active Control1 Intervention
Non-Psychiatric Controls with cannabis use will continue to use cannabis as usual
Group V: Non-Psychiatric Controls without cannabis useActive Control1 Intervention
Non-Psychiatric controls without cannabis use
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency management
2006
Completed Phase 4
~960

Find a Location

Who is running the clinical trial?

Douglas Mental Health University InstituteLead Sponsor
29 Previous Clinical Trials
2,592 Total Patients Enrolled
Rachel Rabin, Ph. D.Principal InvestigatorDouglas Mental Health University Institute

Media Library

Contingency management Clinical Trial Eligibility Overview. Trial Name: NCT05445180 — N/A
Cannabis Use Disorder Research Study Groups: Psychosis patients with cannabis use (Non-abstinent), Non-Psychiatric controls with cannabis use (Abstinent), Non-Psychiatric controls with cannabis use (Non-abstinent), Non-Psychiatric Controls without cannabis use, Psychosis patients with cannabis use (Abstinent)
Cannabis Use Disorder Clinical Trial 2023: Contingency management Highlights & Side Effects. Trial Name: NCT05445180 — N/A
Contingency management 2023 Treatment Timeline for Medical Study. Trial Name: NCT05445180 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current population size of participants in this medical research?

"Absolutely. On clinicaltrials.gov, it is indicated that this study commenced recruitment on April 21st 2022 and was recently revised June 30th 2022. The team behind the trial are in search of 134 participants from a single research center."

Answered by AI

Which patient demographics are eligible for participation in this clinical research?

"This clinical trial seeks 134 individuals with psychotic disorders between the ages of 16 and 80. Eligibility criteria for applicants comprise: a comprehension of either English or French to provide informed consent, habitual cannabis use (defined as weekly consumption over six months) and/or CUD diagnosis congruent to DSM-5 standards, IQ score above 75 on full scale test, diagnostic cohort in accordance with DSM-5 guidelines (applicable only to psychosis patients), stable dose of medication(s) administered over the course two past months (applicable solely to psychosis patients), clinically sound status according PANSS-6 results yielding total scores below 30"

Answered by AI

Are individuals aged thirty and over being included as participants in this research?

"For this clinical trial, the upper and lower age limits for participant selection are 80 years old and 16 years old respectively."

Answered by AI

Is recruitment still underway for this clinical investigation?

"According to the clinicaltrials.gov database, this research trial is still recruiting participants since it was initially posted on April 21st 2022 and last updated June 30th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Florida
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Rachel Rabin 2022. "Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05445180.
All > Mci
~80 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top